Liaoning Chengda Biotechnology Co. Ltd. A
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant h… Read more
Liaoning Chengda Biotechnology Co. Ltd. A (688739) - Total Assets
Latest total assets as of June 2025: CN¥9.79 Billion CNY
Based on the latest financial reports, Liaoning Chengda Biotechnology Co. Ltd. A (688739) holds total assets worth CN¥9.79 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Liaoning Chengda Biotechnology Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how Liaoning Chengda Biotechnology Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Liaoning Chengda Biotechnology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Liaoning Chengda Biotechnology Co. Ltd. A's total assets of CN¥9.79 Billion consist of 70.5% current assets and 29.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 44.7% |
| Accounts Receivable | CN¥1.08 Billion | 10.7% |
| Inventory | CN¥459.94 Million | 4.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥756.15 Million | 7.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Liaoning Chengda Biotechnology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Liaoning Chengda Biotechnology Co. Ltd. A's current assets represent 70.5% of total assets in 2024, an increase from 66.8% in 2019.
- Cash Position: Cash and equivalents constituted 44.7% of total assets in 2024, up from 33.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 3.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 10.7% of total assets.
Liaoning Chengda Biotechnology Co. Ltd. A Competitors by Total Assets
Key competitors of Liaoning Chengda Biotechnology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Liaoning Chengda Biotechnology Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Liaoning Chengda Biotechnology Co. Ltd. A generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Liaoning Chengda Biotechnology Co. Ltd. A generates $ 3.41 in net profit.
Liaoning Chengda Biotechnology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 21.15 | 18.49 | 32.59 |
| Quick Ratio | 19.70 | 17.34 | 30.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.45 Billion | CN¥ 6.63 Billion | CN¥ 7.51 Billion |
Liaoning Chengda Biotechnology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Liaoning Chengda Biotechnology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -0.3% |
| Total Assets | CN¥10.05 Billion |
| Market Capitalization | $602.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Liaoning Chengda Biotechnology Co. Ltd. A's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Liaoning Chengda Biotechnology Co. Ltd. A's assets decreased by 0.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Liaoning Chengda Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual total assets of Liaoning Chengda Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥10.05 Billion | -0.30% |
| 2023-12-31 | CN¥10.08 Billion | +0.25% |
| 2022-12-31 | CN¥10.06 Billion | +2.69% |
| 2021-12-31 | CN¥9.79 Billion | +117.24% |
| 2020-12-31 | CN¥4.51 Billion | +20.67% |
| 2019-12-31 | CN¥3.74 Billion | -- |